内容紹介
Clinical Investigation of the Effects of Filgrastim BS1 on Neutropenia Following Oral Cancer Chemotherapy(TPF Therapy)
Summary
The time for the neutrophil count to recover after subcutaneous injection of filgrastim BS1 or lenograstim was studied in patients suffering from neutropenia following preoperative combined chemotherapy using docetaxel, nedaplatin, or cisplatin(in divided doses for 5 days)and 5-fluorouracil for oral cancer. 1. There was no significant difference in the minimum leukocyte and neutrophil counts after chemotherapy. 2. There was no significant difference in the maximum leukocyte and neutrophil counts after chemotherapy. 3. Time for leukocytes to recover from their minimum count(>4,000/mm3)or for neutrophils to recover from their minimum count(>2,000/mm3)and the number of days on which treatment was administered tended to be shorter in the filgrastim BS1 group. Thus, it was concluded that filgrastim BS1 is just as effective as other prior G-CSF agents in treating patients suffering from neutropenia following chemotherapy(TPF therapy).
要旨
口腔癌に対してdocetaxel,nedaplatinあるいはcisplatinの白金製剤(5日間分割投与),5-fluorouracil 3剤併用術前化学療法(TPF療法)を実施した後,好中球減少を来した患者を対象に,G-CSF製剤としてフィルグラスチムBS1あるいはレノグラスチムを皮下投与し,好中球の回復期間に関して両剤を比較検討した。 1.化学療法後の白血球および好中球数の最低値には有意な差はなかった。2.化学療法後の白血球および好中球数の最高値には有意な差はなかった。3.化学療法後および最低値からの白血球数(>4,000/mm3)あるいは好中球数(>2,000/mm3)の回復期間および投与日数は,フィルグラスチムBS1群のほうが短い傾向にあった。以上より,フィルグラスチムBS1は化学療法(TPF療法)後の好中球減少症の治療に,他の先行G-CSF製剤同様に有用であると考えられた。
目次
Summary
The time for the neutrophil count to recover after subcutaneous injection of filgrastim BS1 or lenograstim was studied in patients suffering from neutropenia following preoperative combined chemotherapy using docetaxel, nedaplatin, or cisplatin(in divided doses for 5 days)and 5-fluorouracil for oral cancer. 1. There was no significant difference in the minimum leukocyte and neutrophil counts after chemotherapy. 2. There was no significant difference in the maximum leukocyte and neutrophil counts after chemotherapy. 3. Time for leukocytes to recover from their minimum count(>4,000/mm3)or for neutrophils to recover from their minimum count(>2,000/mm3)and the number of days on which treatment was administered tended to be shorter in the filgrastim BS1 group. Thus, it was concluded that filgrastim BS1 is just as effective as other prior G-CSF agents in treating patients suffering from neutropenia following chemotherapy(TPF therapy).
要旨
口腔癌に対してdocetaxel,nedaplatinあるいはcisplatinの白金製剤(5日間分割投与),5-fluorouracil 3剤併用術前化学療法(TPF療法)を実施した後,好中球減少を来した患者を対象に,G-CSF製剤としてフィルグラスチムBS1あるいはレノグラスチムを皮下投与し,好中球の回復期間に関して両剤を比較検討した。 1.化学療法後の白血球および好中球数の最低値には有意な差はなかった。2.化学療法後の白血球および好中球数の最高値には有意な差はなかった。3.化学療法後および最低値からの白血球数(>4,000/mm3)あるいは好中球数(>2,000/mm3)の回復期間および投与日数は,フィルグラスチムBS1群のほうが短い傾向にあった。以上より,フィルグラスチムBS1は化学療法(TPF療法)後の好中球減少症の治療に,他の先行G-CSF製剤同様に有用であると考えられた。